Couldn't find anything about the level of improvem
Post# of 148169
(Total Views: 240)
Posted On: 07/29/2019 10:10:48 AM
Couldn't find anything about the level of improvement; odd, but seems like they will present the exact data at an upcoming conference:
https://investors.merck.com/news/press-releas...fault.aspx
"These findings from this innovatively designed trial with KEYTRUDA mark the first time an anti-PD-1 therapy plus chemotherapy has demonstrated a statistically significant improvement in pathological complete response rate as a neoadjuvant, or pre-surgical, segment of treatment for triple-negative breast cancer,” said Dr. Roger M. Perlmutter, president, Merck Research Laboratories. “TNBC is an aggressive malignancy with a high rate of recurrence within the first five years of diagnosis. We are encouraged by these results and plan to discuss these data with health authorities and to present these findings at an upcoming medical congress.”
https://investors.merck.com/news/press-releas...fault.aspx
"These findings from this innovatively designed trial with KEYTRUDA mark the first time an anti-PD-1 therapy plus chemotherapy has demonstrated a statistically significant improvement in pathological complete response rate as a neoadjuvant, or pre-surgical, segment of treatment for triple-negative breast cancer,” said Dr. Roger M. Perlmutter, president, Merck Research Laboratories. “TNBC is an aggressive malignancy with a high rate of recurrence within the first five years of diagnosis. We are encouraged by these results and plan to discuss these data with health authorities and to present these findings at an upcoming medical congress.”
(0)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼